This episode of #ShareScience features Dr. Amy Sheng, a technical account manager at Sino Biological.

Nanobodies are emerging as important tools for tumor diagnosis and treatment due to their small size, simple humanization, low immunogenicity, superior affinity and stability, high penetration, and adequate levels of solubility, and are expected to revolutionize the antibody-based drug therapy. Nanobodies can be widely applied and have shown promising prospects in a wide range of pathologic conditions, such as central nervous system diseases, circulatory system diseases, infectious diseases, and oncological and inflammatory diseases. Especially in the field of cancer immunotherapy, nanobodies can be used for the recognition and therapeutic inactivation of checkpoint inhibitors, activation of antigen-presenting cells (APCs), blocking of immunosuppressive cells, neutralization of immunosuppressive molecules, cytokine regulation, and for the development of CAR-T or CAR-NK cells. Tune in to hear the latest and greatest Industry Insights from Sino Biological.

Interested in antibody screening and discovery? Register for Sino Biological's upcoming webinar on November 2, Antibody Discovery by Single B Cell Screening on Beacon®.

To learn more about Sino Biological, check out their Comprehensive Recombinant Protein Production and Antibody Development Platforms